| Primary |
| Breast Cancer |
53.5% |
| Drug Use For Unknown Indication |
15.2% |
| Product Used For Unknown Indication |
12.1% |
| Breast Cancer Metastatic |
4.7% |
| Prophylaxis |
2.7% |
| Cancer Pain |
1.8% |
| Pain |
1.5% |
| Hypertension |
1.3% |
| Constipation |
1.0% |
| Insomnia |
0.8% |
| Gastritis |
0.8% |
| Nausea |
0.8% |
| Breast Cancer Recurrent |
0.6% |
| Breast Cancer Female |
0.5% |
| Gastritis Prophylaxis |
0.5% |
| Diabetes Mellitus |
0.5% |
| Metastases To Bone |
0.5% |
| Neoplasm Malignant |
0.5% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
0.4% |
| Rash |
0.4% |
|
| Diarrhoea |
18.8% |
| Death |
15.2% |
| Vomiting |
12.1% |
| Rash |
9.5% |
| Nausea |
8.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
5.5% |
| Fatigue |
4.6% |
| Weight Decreased |
4.1% |
| Stomatitis |
3.5% |
| Disease Progression |
2.7% |
| Drug Ineffective |
2.4% |
| Pyrexia |
2.2% |
| Malaise |
1.7% |
| Skin Chapped |
1.6% |
| White Blood Cell Count Decreased |
1.6% |
| Breast Cancer Metastatic |
1.5% |
| Hospitalisation |
1.4% |
| Pain In Extremity |
1.3% |
| Pruritus |
1.2% |
| Skin Discolouration |
1.2% |
|
| Secondary |
| Breast Cancer |
39.5% |
| Product Used For Unknown Indication |
17.1% |
| Prophylaxis |
7.8% |
| Breast Cancer Metastatic |
5.4% |
| Cancer Pain |
5.0% |
| Drug Use For Unknown Indication |
3.8% |
| Insomnia |
2.6% |
| Convulsion |
2.4% |
| Constipation |
1.9% |
| Metastases To Bone |
1.9% |
| Hypertension |
1.7% |
| Gastritis Prophylaxis |
1.6% |
| Brain Oedema |
1.4% |
| Pain |
1.4% |
| Oedema |
1.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
1.2% |
| Prophylaxis Against Diarrhoea |
1.2% |
| Her-2 Positive Breast Cancer |
1.0% |
| Hyperkeratosis |
0.9% |
| Gastritis |
0.9% |
|
| Stomatitis |
14.0% |
| Vomiting |
10.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
10.1% |
| Diarrhoea |
8.4% |
| Pyrexia |
6.6% |
| Rash |
5.7% |
| Cellulitis |
5.4% |
| Decreased Appetite |
4.5% |
| Nausea |
3.9% |
| Brain Oedema |
3.6% |
| Malignant Neoplasm Progression |
3.6% |
| Dehydration |
3.0% |
| Infectious Pleural Effusion |
3.0% |
| Pneumonia |
3.0% |
| Dizziness |
2.7% |
| Pulmonary Embolism |
2.7% |
| Disease Progression |
2.4% |
| Renal Impairment |
2.4% |
| Skin Exfoliation |
2.4% |
| White Blood Cell Count Decreased |
2.4% |
|
| Concomitant |
| Breast Cancer Metastatic |
35.6% |
| Breast Cancer |
25.2% |
| Metastases To Bone |
6.2% |
| Product Used For Unknown Indication |
5.9% |
| Breast Cancer Recurrent |
4.6% |
| Neoplasm Malignant |
3.9% |
| Hypertension |
3.4% |
| Drug Use For Unknown Indication |
3.1% |
| Premedication |
2.0% |
| Depression |
1.7% |
| Pain |
1.7% |
| Type 1 Diabetes Mellitus |
1.5% |
| Prophylaxis |
1.0% |
| Breast Cancer Female |
0.7% |
| Pain In Jaw |
0.7% |
| Menopausal Symptoms |
0.6% |
| Nausea |
0.6% |
| Bone Cancer |
0.5% |
| Stomatitis |
0.5% |
| Chemotherapy |
0.4% |
|
| Disease Progression |
15.0% |
| Weight Decreased |
13.6% |
| Death |
9.5% |
| Vision Blurred |
8.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
5.4% |
| Vomiting |
5.4% |
| Malignant Neoplasm Progression |
4.8% |
| Rash |
4.1% |
| Tumour Invasion |
4.1% |
| Tooth Extraction |
3.4% |
| Diarrhoea |
2.7% |
| Drug Ineffective |
2.7% |
| Ejection Fraction Decreased |
2.7% |
| Febrile Neutropenia |
2.7% |
| Left Ventricular Dysfunction |
2.7% |
| Sepsis |
2.7% |
| Stomatitis |
2.7% |
| Vulvar Dysplasia |
2.7% |
| Acute Myeloid Leukaemia |
2.0% |
| Chronic Obstructive Pulmonary Disease |
2.0% |
|
| Interacting |
| Breast Cancer Metastatic |
39.4% |
| Breast Cancer |
30.3% |
| Product Used For Unknown Indication |
18.2% |
| Convulsion |
12.1% |
|
| Weight Decreased |
58.3% |
| Malignant Neoplasm Progression |
25.0% |
| Drug Interaction |
16.7% |
|
